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Preclinical work in murine models suggests that local radiotherapy plus intratumoral
syngeneic dendritic cells (DC) injection can mediate immunologic tumor eradication. Radio-
therapy affects the immune response to cancer, besides the direct impact on the tumor
cells, and other ways to coordinate immune modulation with radiotherapy have been
explored. We review here the potential for immune-mediated anticancer activity of radi-
ation on tumors. This can be mediated by differential antigen acquisition and presentation
by DC, through changes of lymphocytes’ activation, and changes of tumor susceptibility
to immune clearance. Recent work has implemented the combination of external beam
radiation therapy (EBRT) with intratumoral injection of DC. This included a pilot study of
coordinated intraprostatic, autologous DC injection together with radiation therapy with
ﬁve HLA-A2(+) subjects with high-risk, localized prostate cancer; the protocol used andro-
gen suppression, EBRT (25 fractions, 45 Gy), DC injections after fractions 5, 15, and 25,
and then interstitial radioactive implant. Another was a phase II trial using neo-adjuvant
apoptosis-inducing EBRT plus intra-tumoral DC in soft tissue sarcoma, to test if this would
increase immune activity toward soft tissue sarcoma associated antigens. In the future,
radiation therapy approaches designed to optimize immune stimulation at the level of DC,
lymphocytes, tumor and stroma effects could be evaluated speciﬁcally in clinical trials.
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INTRODUCTION
RADIATION EFFECTS
A conventional view of radiation is an immune attenuator. In this
perspective, damage, and destruction are the effects on living tis-
sues – whether they are tumor, normal stroma, and parenchyma,
or leukocytes. In the medical application of therapeutic radia-
tion, this is a measured induction of apoptosis and other cell
death within a carefully deﬁned volume. The impact of radia-
tion on leukocytes can be viewed in similarly detrimental terms,
whether attenuating lymphocyte numbers as tolerable side effect
(Johnke et al., 2005; Lissoni et al., 2005) a therapeutic effect, such
as part of an allogeneic transplant protocol (Wei et al., 2004; Gupta
et al., 2011), or precipitating a secondary malignancy (Brill et al.,
1962). The measurement of accumulated radiation injuries, such
as micronuclei and DNA breakage in circulating lymphocytes, has
been proposed as a direct assay of individuals’ relative radiosensi-
tivity (Minicucci et al., 2005; Tang et al., 2008; Ishihara et al., 2012);
that sensitivity can be relevant to either toxicity or to treatment
efﬁcacy.
We focus here on the effect of radiation on the bilateral rela-
tionship of tumor with the immune system, not just on the effects
of radiation on the tumor or on the leukocytes, separately. Con-
sidered in isolation, radiation to any particular cell could be
anticipated to have a detrimental impact. However, there is an
opportunity in the interplay of tumor cell death, induced antigen
expression on tumor cells, and inﬂammatory signals from the irra-
diated volume which affect lymphocyte and dendritic cell (DC)
activation. Figure 1 contrasts the perspectives of isolated versus
system effects of irradiation. Immunotherapeutic impacts can be
coordinated with therapeutic tumor irradiation. In this way, the
whole therapeutic effect can exceed the sum of its parts.
PROCESSES OF CELLULAR IMMUNITY
Physiologic process of antigen presentation and lymphocyte acti-
vation are complex processes, and subject to modulation because
of the tumor microenvironment (Fricke and Gabrilovich, 2006).
Immature myeloid cells acquire antigen, whether by vaccination
or through phagocytosis of material in the tumor microenviron-
ment. These cells then mature, with acquisition of cell surface
proteins such asMHCclass I and II onwhichpeptides derived from
the antigen source can be presented, to interact with particular
antigen-speciﬁc idiotypic receptors on T lymphocytes (discussed,
for example, by Liao et al., 2004). Other maturational markers
such as CD80, CD86 facilitate costimulation interactions, particu-
larly the process of activation versus tolerogenic inﬂuence on those
lymphocytes (these illustrated in Topalian et al., 2012, where the
focus is on the PD-1/PDL-1 interaction, for example). The inter-
action of lymphocytes with the antigen-presenting cells, occurs
in lymph nodes to which the DC migrate as part of the mat-
uration process, and the subsequent potential anticancer effect
of lymphocytes then is a consequence of lymphocytes’ expan-
sion within the lymph node, circulation, and penetration into
the tumor mass. Other lymphocyte pathways, such as natural
killer (NK) cells, may be inﬂuenced by T cell activation and the
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tumor microenvironment, but do not require speciﬁc education
and costimulation by DCs. Other antigen-presenting cells, such
as macrophages, and inﬂammatory cells such as neutrophils may
inﬂuence the tumor microenvironment (Fricke and Gabrilovich,
2006) in a way that indirectly, but overwhelmingly alters the
polarization of macrophages, DC, or the activation state effector
lymphocytes. Overall, the potential effect of radiation on the pre-
ponderance or phenotype of many cell types, some of which are
discussed below, could inﬂuence availability of tumor antigens,
the acquisition of the antigens by immature antigen-presenting
cells, the migration of those cells to lymph nodes, the eventual
polarization into tolerogenic or immunogenic phenotype, the efﬁ-
ciency of interaction with lymphocytes, the stimuli leading to
intratumoral migration of lymphocytes, the extent of activation
of the lymphocytes that are within the tumor, and the suscepti-
bility of (still living) tumor cells to immune lysis. As for many
anticancer pharmaceutical interventions, we are only beginning
to understand the inﬂuences that irradiation can effect on this
system.
RADIATION EFFECTS IN ISOLATION
RADIATION EFFECTS: THE TUMOR
The fundamentalmechanismof tumor regression following radio-
therapy is by inductionof DNAdamage in the neoplastic cells. This
accumulation of DNA breaks and consequent insufﬁcient repair is
the trigger for pathways including Bcl2 family apoptotic and anti-
apoptotic proteins, p53-dependent, and independent pathways, or
TRAIL [tumor necrosis factor (TNF)-related apoptosis-inducing
ligand) dependent mechanisms (Maduro et al., 2008; Roos and
Kaina, 2012). However, this basic view is still not a complete
picture of microenvironmental changes within tumor-associated
endothelial cells, inﬂammatory inﬁltrates, or of systemic responses
to the tumor. Areas of higher dose exposure, for example adjacent
to brachytherapy seeds, or at hot-spots inside the bulk of the tumor
may have markedly different pathways to cell death, emphasizing
necrotic mechanisms not apoptotic ones (Nagorsen et al., 2003;
Overwijk et al., 2003; Finkelstein et al., 2004; Klebanoff et al., 2004;
Kakinuma et al., 2007). Additionally, the time course of changes
of antigen expression by the irradiated cells may be relevant, with
different patterns that are dependent on radiotherapy techniques’
dose-rate and energy level (Finkelstein et al., 2011).
Besides the phenomenon of cells dying within an irradiated
tumor, several processes have speciﬁc relevance to immunother-
apy. Some relate to inﬂammation and clearance of antigens within
the irradiated volume. Of the most interest are the processes
that inﬂuence acquisition of a more activated general immune
phenotype or of a more activated tumor-speciﬁc immune phe-
notype. The most dramatic clinical outcome is when a distant
tumor mass regresses, the abscopal effect. Clinical examples
described as case reports (Kingsley, 1975; Postow et al., 2012;
Stamell et al., 2012) and preclinical examples are discussed inmore
detail below. Less apparent outcomes, still with major clinical
impact, may occur as well. These include accelerating or complet-
ing deﬁnitive clearance of the tumor which was being irradiated.
Another important impact can be clearance of other metastatic
disease that was not clinically apparent because it was micro-
scopic; this could lead to prevention of systemic recurrence as
a consequence of radiation-triggered immune activation in the
primary tumor.
Moravan et al. (2011) describe persistent inﬂammatory changes
consisting of neutrophil and T cell inﬁltrates, within brains of
C57BL/6 mice, as a speciﬁc and lasting effect of irradiation, in the
absence of tumor. The protein CXCL16 (CXC motif ligand 16)
is released from irradiated tumor. This binds the CXCR6 recep-
tor, found on activated effector T cells (Matsumura and Demaria,
2010). A murine model, including use of a CXCR6 knockout con-
trol mouse, demonstrated this mechanism of T cell inﬁltration
to the tumor (Matsumura et al., 2008). Another group, survey-
ing 63 cytokines, found that CXCL16 levels went down after
30 Gy irradiation of skin (not tumor) in a murine model (Xiao
et al., 2013). The speciﬁc relevance in clinical use remains to be
elucidated.
High mobility group box 1 (HMGB1) is a protein which is
released from some dying cells, including tumor cells killed by
anthracyclines (Fucikova et al., 2011), and in a hyperthermia and
radiation combination model (Schildkopf et al., 2010), and with
radiation and chemotherapy combination treatments for colorec-
tal cancer cell lines, particularly with the combination (Frey et al.,
2012). The HMGB1 effect on DC can include maturation and a
chronic inﬂammatory state (Fucikova et al., 2011). It is an impor-
tant questionwhether a clinically relevant (adverse) changes of DC
phenotype (Popovic et al., 2006) or of downstream T cell effec-
tor activity (Liu et al., 2011) occur from tumor therapy-derived
HMGB1. It is not clear if irradiation protocols leading to higher
or lower systemic HMGB1 levels would be better for induction of
a general anticancer immunophenotype.
In a clinical report on patients receiving primary, curative-
intent fractionated external beam radiation therapy (EBRT) for
prostate cancer, Hurwitz et al. (2010) describe observation of con-
sistent systemic changes. These were increases of (systemic) levels
of tumor-derived protein Hsp72 (heat shock protein), and of
inﬂammatory cytokines IL-6 and TNF-α. Circulating CD8+ T
cells and NK cells showed increases of 2.1- and 3.2-fold, respec-
tively. While the changes of these particular proteins or leukocytes
do not directly prove a functional augmentation of the systemic
antitumor response, they are illustrative of impacts on the host’s
overall immunophenotype because of events within the tumor.
RADIATION EFFECTS: THE LYMPHOCYTES
There is not signiﬁcant systemic lymphopenia from prostate can-
cer EBRT, our group has observed (Finkelstein et al., 2012d).
Others suggest that hypofractionated radiation therapy can medi-
ate a decrease in CD4+ and CD8+ lymphocyte number, but not of
NKandof B lymphocytes. This effectwas counterbalanced in those
patients receiving combined androgen blockade, with gosere-
lin and ﬂutamide, suggesting a converse effect of testosterone
suppression (Johnke et al., 2005). In a report describing serial
ﬂow cytometry analyses lymphocytes of cervical cancer patients
(stage IIB through IVA) being treated with larger ﬁeld external
beam irradiation and concomitant intracavitary brachytherapy
again it was observed that total lymphocyte count went down.
In the patients without progressive disease, the CD8+ T cell
and NK cell percentages increased. The authors commented that
these increases are consistent with a role of CD8+ T cell and
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FIGURE 1 | (A) Radiation effects in isolation. (B) Downstream theoretically favorable immune modulation after irradiation.
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NK cell in deﬁnitive tumor clearance (Lissoni et al., 2005). This
is comparable with the CXCL16 mechanism discussed above
(Matsumura et al., 2008).
Brachytherapy is a radiation therapy modality with markedly
different kinetics of radiation exposure. In brachytherapy seed
placement (Iodine 125 or Palladium 103) or radioembolization
with Yttrium 90 microspheres (Carr and Metes, 2012), there is a
longer exposure to radiation thanwith conventional external beam
treatment, with potential for most of the circulating blood volume
be transiently in very close proximity of the radioactive source.
Carr and Metes (2012) evaluated the impact on lymphocytes of
Yttrium 90 embolization of hepatocellular cancer, with ﬁnding
that there was an early decrease on T cell number (both CD4+
and CD8+) and B cell number (assayed by CD19), but not on NK
cells or neutrophils. Over time, the deﬁcits persisted signiﬁcantly
for some patients; an impaired recovery was associated with worse
prognosis. This could reﬂect a disease impact on the lymphocyte
repopulation, more so than an ongoing radio-isotope mediated
suppression (Lissoni et al., 2005).
RADIATION EFFECTS: THE DENDRITIC CELLS
The tumor microenvironment has potential to modulate the phe-
notype of DC to favor the pathologic tolerance of the tumor
(Fricke and Gabrilovich, 2006). The focus of the therapeutic ratio-
nale for placing DC into the tumor microenvironment (discussed
below) is that radiation will alter that effect, but the impact of
radiation onto DC should be considered separately. Isolating the
issue, higher doses of radiation (25–30 Gy) than would be used
in a standard fractionated radiotherapy plan (generally less than
about 2 Gy), were studied in an experimental setting assaying ex
vivo priming of DC by Cao et al. (2004), in a report with a focus
on multiple sclerosis patients. They report that the irradiated DC
would still stimulate T cell proliferation in the MLR (mixed lym-
phocyte reaction) assay but at a lower level, and with higher T
cell production of IL-2 and IL-4. Phenotypic changes related to
maturational markers were observed, with lower levels of CD80
(B7.1), CD86 (B7.2), and HLA-DR on the DC.
On the other hand, Jahns et al. (2011) studied ex vivo prepara-
tions of leukocytes, focusing on quantitative functional impact on
DC versus the impact onto lymphocytes. They found that DC are
less sensitive to apoptosis than lymphocytes, and maintained the
same functional level (in terms of cytokine proﬁles, surface mark-
ers, and maturation) after a radiation dose that impaired T cell
function. In particular, there was lower expression of DC matura-
tional markers (CD80, CD86, and HLA-DR) and the T cells had
less activation. Bogdándi et al. (2010) tested splenocytes of mice
(C57BL/6) exposed to increasing doses of radiation, up to 2 Gy,
with the most sensitivity for B cells (at 2 Gy), but more resistance
in the NK cells, DC and regulatory T cells, thus observing a similar
pattern of relative sensitivity to irradiation. The speciﬁc impact of
acquisition or suppression of these DC maturational markers on
clinical outcomes must be studied empirically to address whether
the net change was favorable.
Liao et al. (2004) isolated the issue of irradiation of DC, again
in a model system with C57BL/6 mice, with B16 melanoma. The
loading of the DC was by transfection with adenovirus engi-
neered to express the MART-1 antigen, termed AdVMART1; the
B16 melanoma expresses the MART-1 antigen, as do the major-
ity of human melanoma specimens. Murine DC were obtained
from bone marrow (femur and tibia), and cultured and trans-
fected in vitro, after which they express the (full length, human)
hMART-1 protein, and also the immunodominant MART-127−35
peptide. The DC irradiation protocol consisted of 10 Gy, in a
single fraction in just over 2 min. To assay the effect of irradia-
tion of the DC on the class 1 antigen-presentation process, DC
culture was irradiated (or not treated), then (immediately) trans-
fected with AdvMART1, then injected into (non-tumor bearing)
mice; this was repeated at a 7 days’ interval. Then after an interval
of 10–14 days, the T lymphocytes from the spleen were assayed
with the ﬁnding that acquisition of elevated level of T lympho-
cytes with speciﬁcity for the test antigen (MART-127−35 peptide)
was eliminated by the radiation protocol. Similarly, subsequent
challenge to test mice with B16 melanoma injection showed pro-
tection only for un-irradiated DC treatment, but not for mice not
injected with DC, and not for mice injected with DC that had been
treated on the irradiation protocol. Further, they investigated the
potential maturation-related mechanisms for irradiation of DC
affecting the capacity or tendency to present the class I epitopes of
MART1; they observed that maturational markers of DC (partic-
ularly CD80, CD86, and MHC class I and II) were not changed.
In testing the response to CD40L and interferon gamma (IFN-γ)
stimulation (maturational signals), although there was (pretreat-
ment) a decrease of some maturational markers (CD80, CD83,
MHC class II), after treatment, the difference was not observed.
Looking at those results, the effect of DC irradiation appears to be
neutral or suppressive (Liao et al., 2004).
In a next set of investigations, to test for antigen-presentation
effects isolated from antigen processing, a modiﬁed DC/tumor
system was used. The HLA-A2.1/Kb transgenic mice bear human
HLA-A2; the modiﬁed tumor B-16A2/Kb does as well. When DC
from these mice were prepared and treated as above, but then
instead of being transduced with the adenovirus, the DC were
instead pulsed with the immunodominant MART-127−35 pep-
tide. These DC (or control DC that were pulsed but had not
been irradiated) were use to vaccinate mice; 10 days after the last
vaccination the mice were challenged with B-16A2/Kb tumor, it
was found that mice in the group treated with the DC that had
been irradiated had better survival, and a higher induced immu-
nity as measured by IFN-γ production in an ELISPOT assay with
the MART-127−35 peptide (Liao et al., 2004). Thus, the irradi-
ation of DC with 10 Gy in this model system, where antigen
processing and maturation were not much changed or a little
worse, showed a better anticancer effect, attributed to improved
presentation.
THE TUMOR MICROENVIRONMENT
LOCAL IMMUNE SUPPRESSION
The immune system in the cancer-bearing host cancer has defects
that allow the tumor cells to evade clearance. Theway that immune
privilege is maintained is heterogeneous across different disease
stages and patients. Some characterizations can be in terms of
DC phenotype; an excess of myeloid-derived suppressor cells
(MDSC) that are not mature DC, but rather suppress DC func-
tion to impair anticancer immunity (Almand et al., 2000). Other
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characterization can focus on the tumor microenvironment. That
kind of suppression can be observed to operate through elabora-
tion of particular proteinswhich have receptors onDCandMDSC,
in some models and some clinical examples. Those microenvi-
ronment derived molecules include vascular endothelial growth
factor (VEGF), tumor growth factor β (TGF-β), reactive oxygen
species, the enzyme indoleamine-2,3-deoxygenase, granulocyte-
macrophage colony stimulating factor (GM-CSF), interleukin-8,
interleukin-10 (reviewed by Fricke and Gabrilovich, 2006). Spe-
ciﬁc inhibition of these pathways can have a favorable impact
on DC phenotype and the capacity for meaningful immunologi-
cally mediated anticancer response, for example a murine tumor
model was induced to be immunologically rejected by use ofVEGF
depleting antibody (Gabrilovich et al., 1999); a clinical trial using
sequential bevacizumab (humanized anti-VEGF antibody, Roche
USA, Indianapolis, IN) and then low dose subcutaneous IL-2 did
not demonstrate a signiﬁcant clinical impact nor impact on DC
phenotype for VEGF depletion (Finkelstein et al., 2010). However,
in a clinical trial utilizing another VEGF chelation strategy, with a
similar testing scheme, foundno functional improvement as a con-
sequence of ziv-aﬂibercept treatment (formerly “aﬂibercept,” also
called VEGF-trap; Sanoﬁ-Aventis, Bridgewater, NJ). Changes that
were observable as ﬂow cytometry deﬁned phenotypic changes of
DC from patients following treatment, however, were favorable
(Fricke et al., 2007).
RATIONAL PLACEMENT OF DC VERSUS RADIATION THERAPY TIMING
Almost any radiation therapy protocol can be analyzed with
respect to its theoretical immune impact, either on an anatomic
or temporal perspective. From an anatomic perspective, regions
of the treatment target volume with the highest doses could be
anticipated to have higher and faster peaks of tumor cell death,
and availability of antigenic material. Regions of lower dose could
have radiation induced changes of antigen expression on the
tumor cells. Leukocytes and stroma also would respond to irra-
diation, with variable amounts of induced regional inﬂammatory
cytokines, or penetration with other inﬂammatory cells, such as
macrophages and neutrophils. Since DC can be anticipated to
potentially become activated when placed into this environment,
that is a key rationale for intratumoral, versus intravenous or
subcutaneous administration.
Considering a temporal perspective, the best time to introduce
DC into an irradiated tumor ismuch less clearly deﬁned. The onset
of inﬂammatory changes may have a signiﬁcant latency, particu-
larly in conventionally fractionated treatment plans, with a high
number of treatment fractions in the 180–200 cGy range. Place-
ment of DC too early or too late could result in their exposure to a
microenvironment more resembling an intact (immunosuppres-
sive) tumor. The onset of apoptosis or other cell death, or changes
of antigen expression on the tumors themselves is more difﬁcult
to predict in clinical tumors – when would DC have the richest
supply? The potential that injected DC themselves would be irra-
diated, after acquiring antigen, but before migration out to lymph
nodes also must be considered. The migration time appears rela-
tively fast (on the order of a couple of days), but as Liao et al. (2004)
found, the possibility of enhanced antigen presentation after DC
irradiation is another theoretically favorable consideration.
INTRODUCTION OF DC INTO THE TUMOR LOCALE
Nikitina andGabrilovich (2001) initially described the basicmodel
of intratumoral DC injection coordinated with sub-curative irra-
diation of the primary tumor, in a model system using methA
sarcoma (in Balb/Cmice) andC3 tumor (inC57BL/6 femalemice)
tumors. Key ﬁndings for the combination treatment group (but
not for the monotherapies or untreated controls) were longer sur-
vival of themice, with higher T cell titer of tumor-speciﬁc tetramer
peptides, and higher CD8 T cell response to tumor-speciﬁc pep-
tides. Additionally DCs obtained from spleens of syngeneic mice
and marked with ﬂuorescent tracer that were injected subcuta-
neously were demonstrated to track into the irradiated tumor.
Further, the T cell-mediated immunity was sufﬁcient to reject
tumor rechallenge. In sum, the unmanipulated DC that were
placed into irradiated tumor-mediated systemic, lasting antitu-
mor immunity, without any other systemic modulation (Nikitina
and Gabrilovich, 2001).
In another murine tumor system (C57BL/6 female mice with
the D5 tumor, which is a poorly immunogenic subclone the
B16-BL6 melanoma, and with the MCA205 ﬁbrosarcoma), Teitz-
Tennenbaum et al. (2003) observed superior survival in mice
treated with a combined radiation and intratumoral DC injec-
tion protocol. Further they found that loading of the DC with
antigen in situ was superior to ex vivo loading with irradiated
tumor lysate. This contributes to support the idea of particular
microenvironmental attributes of the irradiated tumor that medi-
ate the changes on DC function and the consequent antitumor
immune effect (Teitz-Tennenbaum et al., 2003). In further work
with the D5 tumor, they found that the loading and presentation
of D5-associated antigens by DC was enhanced by D5 irradia-
tion, independent of the low level of tumor cell death that was
directly induced by radiation. Finally, trafﬁcking of DC to regional
tumors was better after tumor irradiation (Teitz-Tennenbaum
et al., 2008), consistent with the ﬁndings of the earlier report dis-
cussed above (Nikitina andGabrilovich, 2001). On the other hand,
assays for several inﬂammatory cytokines (using cultures of tumor
cells), including IL-12p70, TNF-α, IFN-γ, IL-6, and IL-10 did not
show changes following the tumor irradiation, and tumor-speciﬁc
CD8+ T cells did not accumulate in the tumor (Teitz-Tennenbaum
et al., 2008).
CLINICAL TRIALS OF RADIATION PLUS DENDRITIC CELLS
INTRATUMORAL DC INJECTION
Several groups have developed clinical trials toward a goal of
more effective anticancer immune response by tumor irradia-
tion coordinated with intratumoral placement of DC. Primary
radiation therapy for treatment of clinically localized prostate
cancer was studied in a pilot trial, by our group (Finkelstein
et al., 2012a). While the technique of intraprostatic injection was
described generations ago, in a canine model addressing ther-
apy of benign hypertrophy (O’Conor and Ladd, 1936), this is
the initial trial of intraprostatic injection of apheresis derived
autologous DC. There are several features of the clinical scenario
that could be favorable. These include the expectation that the
local therapy could be deﬁnitive, the accessibility for an injec-
tion technique that can be standardized, and simultaneous use of
androgen suppression, which may favor an increased capacity for
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immune response (Windmill and Lee, 1999; Johnke et al., 2005).
Further, the bulk of residual (metastatic, extraprostatic) disease
should be microscopic, at worst, in well-selected patients, and
should have amulti-year latency until detectable recurrence,which
could allowing time for immune clearance to go to completion.
Disadvantages of this system, conversely, are that no immedi-
ate therapeutic effect is discernible. By limiting the inclusion
to individuals with HLA-A*0201 haplotypes, it was hoped that
it would thus be feasible to use an immunological endpoint to
give a readout of an acquisition of a higher titer-speciﬁc CD8+
CTL. To this end, serial assays of the titer of T lymphocytes by
response to stimulation with class 1-associated peptides were used
with the ELISpot (enzyme-linked immunosorbent spot-forming)
IFN-γ assay. This endpoint tested for speciﬁcity to the peptides,
derived from PSA, PSMA, PAP, Her2/neu, and p53, represent-
ing prostate-associated and prostate cancer-associated proteins
(Finkelstein et al., 2012a).
Inclusion required localized cancers, without radiologically
identiﬁed metastasis, but with high-risk features (T-stage, PSA,
Gleason score) for eventual recurrence. The ﬁve patients were
treated with a conventional therapy schedule of 28 months’ andro-
gen suppression, 45 cGy EBRT over 25 fractions, which was then
followed by brachytherapy seed placement. Autologous DC were
prepared from a single pretreatment apheresis, and injected after
the 5th, 15th, and 25th radiation therapy fraction, in each case on
a Friday, so as to give the injected DC about 72 h to potentially
migrate out from the radiotherapy ﬁeld, before the next (6th or
16th) fraction on the following Monday. Overall, the apheresis
and injections were well tolerated. Some patients had detectable
increases of titers for someof thepeptides, but persisting elevations
were not apparent. The low number of patients, and the het-
erogeneity of disease features, precludes a meaningful long-term
efﬁcacy assessment (Finkelstein et al., 2012a).
A second trial developed in our group addressed combined
neo-adjuvant apoptosis-inducing EBRT plus intratumoral DC
injection in larger group of patients, with soft tissue sarcoma (STS)
diagnoses. The immunologic objective was to test for detectable
increase of T lymphocyte titer on testing with autologous STS
tumor cell lysate, using an ELISPOT assay (Finkelstein et al.,
2012b). Patients with clinical stage T2N0M0 high-grade STS of
the extremity, trunk, or chest wall were treated with standard
neo-adjuvant EBRT 5040 cGy in 28 fractions of 180 cGy coor-
dinated with additional DC injection, after weeks 2, 3, and 4.
The DC were prepared from a pretreatment apheresis, ex vivo
expansion and culture, and given as intratumoral injection of 10
million DC.
Secondary analyses included functional T cell activity, toxi-
city tabulation, primary tumor responses, and analysis of DC
migration to lymph nodes, in vivo. Seventeen patients completed
neo-adjuvant EBRT with and DC injection. Fifty-two per cent
showed anti-autologous tumor cell immune responses, as deter-
mined using pre- and post-treatment ELISpot assays (Finkelstein
et al., 2012b). This titer increased after the last DC injection.
Additionally, chromium release assays revealed that after the
treatment there was a statistically signiﬁcant improvement of the
functional cell-killing response to autologous STS lysate. Exam-
ination of the tumor from the post-radiation, deﬁnitive-intent
surgery showed that the combination treatment was associated
with a dramatic accumulation of intratumoral T cells. Presence
of CD4+ T cells in the tumor positively correlated with tumor-
speciﬁc immune responses that developed following combined
therapy. Accumulation of MDSC but not of regulatory T cells neg-
atively correlatedwith the development of tumor-speciﬁc immune
responses.
The treatment was well tolerated, with no toxicity higher than
grade 2 was observed during combined DC/EBRT. Post-operative
wound complications were observed in ﬁve of the 17 patients
(29%), applying the NCIC criteria of a secondary operation for
wound repair or wound management without secondary oper-
ation. Twelve of 17 patients (71%) were progression free after
1 year.
Image-guided visualization of cellular-based vaccine migration
was demonstrated for each patient. Experimentswith 111In labeled
DCs demonstrated that these antigen-presenting cells need at least
48 h to start to migrate from tumor site (Finkelstein et al., 2012b).
This experience led to a multi-institutional trial which is currently
accruing (Finkelstein et al., 2012c).
CONCLUSION
The coming years offer opportunities to transform the phe-
nomenon of radiotherapy-induced anticancer immune response
from isolated case reports into a predictable therapeutic goal. To
this end, several components and perspectives must be uniﬁed
and coordinated. One is the understanding of how to use systemic
therapies to make the host lymphocyte compartment and antigen-
presenting cell compartments be primed for stimulation. Some
examples of immune modulators with the potential to be having
a signiﬁcant impact on the phenotypes of the DC compartment
include TLR9 agonists (Brody et al., 2010; Kim et al., 2012; Zhang
et al., 2012) all trans retinoic acid (Mirza et al., 2006), inhibitors
of VEGF, TGF-β, or use of other cytokines (Antony et al., 2005;
Charo et al., 2005; Gattinoni et al., 2005; Klebanoff et al., 2005,
2011; Zeng et al., 2005; Seung et al., 2012). Comparably, stimula-
tion of the lymphocyte compartment with checkpoint inhibitors
and cytokines also appears poised to make a signiﬁcant contribu-
tion to clinical practice. It will be of interest to see if radiation
therapy can be systematically used to advantage in combinations
with those new agents as well.
Another component will be the ways to provide tumor-
associated antigen to the immune system. While recombinant
vaccines and tumor lysates and synthetic peptides have attributes
of convenience and deﬁnable antigen sets, they cannot be consid-
ered interchangeable with tumor irradiation as a source. Unique
features of tumor irradiation include simultaneous elaboration of
subtle microenvironmental changes with the capacity to improve
antigen presentation, total tumor as a source of antigen, elab-
oration of radiation-induced antigens, and provision of antigen
even before or independent of radiation-induced cell kill. Further,
evolving ﬂexibility of radiation technique, particularly in relation
to conventional fractionation, hypofractionation, brachytherapy,
stereotactic radiosurgery techniques, and high intratumoral dose
exposure may be particularly of interest for optimization of
antigen production and repolarization of the tumor microen-
vironment. The best way for radiation to trigger an abscopal
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response may be related to tumor effect, DC effect, lymphocyte
effects, or indirect modulation of the way the tumor is affecting
leukocyte compartments.
A third component of interest is cellular therapy, particularly
intratumoral DC injection – many questions about timing with
respect to irradiation, details of ex vivo preparation remain to be
addressed empirically. Optimal host preparation, patient selec-
tion, and antigen loading could improve outcomes as well. The
best volume and number of injected DC merits empiric study.
Finally, as a necessary part of clinical development, there must be
some focus on speciﬁc diagnoses.
In summary, it is clear that radiation is a modulator of the
interaction of the tumor and immune compartments, and their
relationships with each other. Careful study of the microenviron-
ment of the irradiated tumor should lead to exciting opportunities
for putatively localized anticancer treatments to be leveraged
to make the irradiated tumor a catalyst for systemic anticancer
response.
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